Trials / Unknown
UnknownNCT05263869
A Study of MRG002 in Treatment of Advanced HER-2 Positive Breast Cancer Patients
An Open-label, Multi-center, Single-arm Phase II Clinical Study to Evaluate the Efficacy and Safety of MRG002 in Advanced HER-2 Positive Breast Cancer Patients Previously Treated With Trastuzumab and TKIs (Magic-009)
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 99 (estimated)
- Sponsor
- Shanghai Miracogen Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG002 in patients with HER2 positive breast cancer with liver metastases.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MRG002 | Administrated intravenously |
Timeline
- Start date
- 2022-03-23
- Primary completion
- 2022-12-01
- Completion
- 2023-10-01
- First posted
- 2022-03-03
- Last updated
- 2022-12-02
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05263869. Inclusion in this directory is not an endorsement.